Literature DB >> 3954622

Failure of immunosuppression with a ten- to 14-day course of high-dose intravenous cyclophosphamide to alter the progression of amyotrophic lateral sclerosis.

R H Brown, S L Hauser, H Harrington, H L Weiner.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a progressive disorder of the nervous system for which there is no known treatment. Because recent studies have suggested that there may be abnormalities of the immune function in patients with ALS and since we have found a beneficial effect from a short course of intensive immunosuppression with cyclophosphamide in progressive multiple sclerosis, we treated six patients with ALS with a ten- to 14-day course of intensive immunosuppression in a pilot study. At 18 months following therapy, all patients showed a continued progression of the disease; four of the six patients died. We conclude that this form of immunosuppression does not alter the course of ALS.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3954622     DOI: 10.1001/archneur.1986.00520040063021

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  12 in total

1.  Amyotrophic Lateral Sclerosis.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-01       Impact factor: 3.598

Review 2.  Microglia and C9orf72 in neuroinflammation and ALS and frontotemporal dementia.

Authors:  Deepti Lall; Robert H Baloh
Journal:  J Clin Invest       Date:  2017-07-24       Impact factor: 14.808

3.  Impact of peripheral immune status on central molecular responses to facial nerve axotomy.

Authors:  D O Setter; E M Runge; N D Schartz; F M Kennedy; B L Brown; K P McMillan; W M Miller; K M Shah; M M Haulcomb; V M Sanders; K J Jones
Journal:  Brain Behav Immun       Date:  2017-10-10       Impact factor: 7.217

Review 4.  Immunological findings in amyotrophic lateral sclerosis.

Authors:  J P Antel; N R Cashman
Journal:  Springer Semin Immunopathol       Date:  1995

5.  Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS.

Authors:  Oleg Butovsky; Shafiuddin Siddiqui; Galina Gabriely; Amanda J Lanser; Ben Dake; Gopal Murugaiyan; Camille E Doykan; Pauline M Wu; Reddy R Gali; Lakshmanan K Iyer; Robert Lawson; James Berry; Anna M Krichevsky; Merit E Cudkowicz; Howard L Weiner
Journal:  J Clin Invest       Date:  2012-08-06       Impact factor: 14.808

6.  Autoimmunity in amyotrophic lateral sclerosis: past and present.

Authors:  Mario Rafael Pagani; Laura Elisabeth Gonzalez; Osvaldo Daniel Uchitel
Journal:  Neurol Res Int       Date:  2011-08-01

Review 7.  Neuroimmunity dynamics and the development of therapeutic strategies for amyotrophic lateral sclerosis.

Authors:  Melissa Bowerman; Thierry Vincent; Frédérique Scamps; Florence E Perrin; William Camu; Cédric Raoul
Journal:  Front Cell Neurosci       Date:  2013-11-19       Impact factor: 5.505

8.  LRP4 antibodies in serum and CSF from amyotrophic lateral sclerosis patients.

Authors:  John S Tzartos; Paraskevi Zisimopoulou; Michael Rentzos; Nikos Karandreas; Vasiliki Zouvelou; Panagiota Evangelakou; Anastasios Tsonis; Thomas Thomaidis; Giuseppe Lauria; Francesca Andreetta; Renato Mantegazza; Socrates J Tzartos
Journal:  Ann Clin Transl Neurol       Date:  2013-12-30       Impact factor: 4.511

Review 9.  Immunoablation and Stem Cell Transplantation in Amyotrophic Lateral Sclerosis: The Ultimate Test for the Autoimmune Pathogenesis Hypothesis.

Authors:  A Arturo Leis; Mark A Ross; Joseph L Verheijde; Jose F Leis
Journal:  Front Neurol       Date:  2016-02-11       Impact factor: 4.003

Review 10.  Cellular therapy to target neuroinflammation in amyotrophic lateral sclerosis.

Authors:  Federica Rizzo; Giulietta Riboldi; Sabrina Salani; Monica Nizzardo; Chiara Simone; Stefania Corti; Eva Hedlund
Journal:  Cell Mol Life Sci       Date:  2013-10-08       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.